Trial record 19 of 496 for:    autism

Evaluation of the French Version of Screening Questionnaires for Autism and Asperger Syndrome: AQ, EQ and SQ

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2007 by Groupe Francais d'Epidemiologie Psychiatrique.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Joint Clinical Research Center
Information provided by:
Groupe Francais d'Epidemiologie Psychiatrique
ClinicalTrials.gov Identifier:
NCT00505830
First received: July 23, 2007
Last updated: NA
Last verified: July 2007
History: No changes posted
  Purpose

Autism is considered as an invading disorder of the development. Asperger Syndrome (AS) is a particular form of autism and is difficult to diagnose. The Autism Spectrum Quotient (AQ) has been developed in order to measure the degree of autistic traits in autistic adolescent with normal intelligence (Baron-Cohen et al. 2001, 2006). AQ comprises 50 questions, with 5 groups of 10 questions assessing imagination, social skills, attention switching, attention to detail and communication skills. Each of these items scores 1 point if the respondent records abnormal or autistic like behaviour. The minimum score on the AQ is 0 and the maximum 50.

The principal objective of this study is to evaluate the accuracy of the French version of Autism Spectrum Quotient questionnaire.

Secondary objectives are to:

Evaluate if EQ and SQ can distinguish adolescents without psychiatric syndromes from those with classical autism or AS.

Evaluate if AQ, EQ and SQ can distinguish adolescents with psychiatric disorders from autistic adolescents.

Define the threshold of positivity for the 3 questionnaires.


Condition Intervention
Asperger Syndrome
Autism
Other: questionnaires

Study Type: Observational
Study Design: Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Longitudinal
Official Title: Evaluation of the French Version of Screening Questionnaires for Autism and Asperger Syndrome : Autism Spectrum Quotient (AQ) Empathy Quotient (EQ) and Systemizing Quotient (SQ)

Resource links provided by NLM:


Further study details as provided by Groupe Francais d'Epidemiologie Psychiatrique:

Estimated Enrollment: 450
Study Start Date: July 2007
Estimated Study Completion Date: July 2009
Groups/Cohorts Assigned Interventions
Case: 1
50 adolescents with AS or high functioning autism (HFS) diagnosed by psychiatrists using established criteria and with an IQ >85.
Other: questionnaires

Primary outcome:

Autism Spectrum Quotient (AQ)

Secondary outcome measure:

Empathy quotient (EQ) Systemizing quotient (SQ) WISC III or WISC IV ADOS score ADI score

Case: 2
50 adolescents with AS or classical autism diagnosed by psychiatrists using established criteria 70<IQ<84.
Other: questionnaires

Primary outcome:

Autism Spectrum Quotient (AQ)

Secondary outcome measure:

Empathy quotient (EQ) Systemizing quotient (SQ) WISC III or WISC IV ADOS score ADI score

Control: 3
50 adolescents with psychiatric disorders but no autism syndrom.
Other: questionnaires

Primary outcome:

Autism Spectrum Quotient (AQ)

Secondary outcome measure:

Empathy quotient (EQ) Systemizing quotient (SQ) WISC III or WISC IV ADOS score ADI score

Control: 4
Sample of 50 healthy adolescents selected randomly from 200.
Other: questionnaires

Primary outcome:

Autism Spectrum Quotient (AQ)

Secondary outcome measure:

Empathy quotient (EQ) Systemizing quotient (SQ) WISC III or WISC IV ADOS score ADI score


Detailed Description:

4 groups of participants will be screened with the questionnaires: Group 1: 50 adolescents with AS or high functioning autism (HFS) diagnosed by psychiatrists using established criteria and with an IQ >85.

Group 2: 50 adolescents with AS or classical autism diagnosed by psychiatrists using established criteria 70<IQ<84.

Group 3: 50 adolescents with psychiatric disorders. Group 4: Sample of 50 healthy adolescents selected randomly from 200. The questionnaires are given to the parents of adolescents during the first meeting. Parents are invited to send them back to the clinical investigation centre of Lyon (France).

Multicentre study: 8 clinical centres and 18 paediatricians

  Eligibility

Ages Eligible for Study:   12 Years to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Group 1 (AS/HFA) and 2 (AS/classic autism) :

  • Boys and girls aged 12 to 18
  • Patients with autism or Asperger syndrome according to the diagnostic criteria (ICD 10)
  • Patients receiving education in an ordinary school
  • IQ>70

Group 3 (adolescents with psychiatric disorders):

  • Boys and girls aged 12 to 18
  • Patients hospitalized on a psychiatric ward or at a psychiatrics patient visit or psychiatric consultation wit hout autistic syndrome
  • Patients receiving education in an ordinary school when not in hospital

Group 4 (adolescent without psychiatric syndrome):

  • Boys and girls aged 12 to 18
  • Patients receiving education in an ordinary school

Exclusion Criteria:

For all groups :

  • Problem with language or comprehension
  • Participants who have not given their consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00505830

Contacts
Contact: Jean-Pierre Vignat, MDH +33 4 37 90 11 75 jpvignat@ch-st-jean-de-dieu-lyon.fr

Locations
France
Centre Hospitalier Saint Jean de Dieu Recruiting
Lyon, France
Contact: Sabine Manificat, MDH    +33 4 37 90 12 96    smanificat@arhm-sjd.fr   
Contact: Berhouz Kassai, MD, PhD       bk@upcl.univ-lyon1.fr   
Sponsors and Collaborators
Groupe Francais d'Epidemiologie Psychiatrique
Joint Clinical Research Center
Investigators
Principal Investigator: Sabine Manificat, MDH Centre Hospitalier Saint Jean de Dieu
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00505830     History of Changes
Other Study ID Numbers: Autisme AQ
Study First Received: July 23, 2007
Last Updated: July 23, 2007
Health Authority: France: Ministry of Health

Keywords provided by Groupe Francais d'Epidemiologie Psychiatrique:
Asperger Syndrom
Autism Quotient
French version
screening
diagnostic test
accuracy

Additional relevant MeSH terms:
Autistic Disorder
Asperger Syndrome
Child Development Disorders, Pervasive
Mental Disorders Diagnosed in Childhood
Mental Disorders

ClinicalTrials.gov processed this record on August 01, 2014